US Patent Issued to LUDWIG INSTITUTE FOR CANCER RESEARCH, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS on Sept. 15 for "Humanized and variant TGF-Beta3 specific antibodies and methods and uses thereof" (American, Swiss Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,735,475, issued on Sept. 15, was assigned to LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (Zurich) and CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (Lausanne, Switzerland).

"Humanized and variant TGF-Beta3 specific antibodies and methods and uses thereof" was invented by Gerd Ritter (New York) and Steven Dunn (Epalinges, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "Antibodies, particularly humanized antibodies and variant antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-Beta3) are provided, recognizing human and mouse TGF-Beta3, particularly antibodies and fragments that do not recognize or bind TGF-Beta1 or...